Biomarker of Acute Exacerbation of COPD

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04963244

Enrollment

Registered

2021-07-15

Start date

2018-04-01

Completion date

2021-06-01

Last updated

2021-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Exacerbation

Keywords

chronic obstructive pulmonary disease, acute exacerbation, transcriptomic, pathogenesis, biomarkers

Brief summary

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is the main factor that leads to the deterioration of the disease. Currently, the diagnosis of AECOPD mainly relies on clinical manifestations, and good predictors or biomarkers are lacking. This study aims to explain the gene expression changes related to the disease at the transcriptional level and validate it in multiple levels, reveal specific biomarkers and potential pathogenesis, to provide a research basis for the diagnosis and treatment of AECOPD.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

40 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

For stable COPD: Inclusion Criteria: 1. Over 40 years old. 2. in line with the diagnostic criteria in GOLD 2018. 3. with the ability to sign informed consent. 4. can be followed up according to the study protocol.

Exclusion criteria

1. with other pulmonary diseases (such as lung cancer, sarcoidosis, tuberculosis, pulmonary fibrosis, cystic fibrosis) and severe α1-antitrypsin deficiency. 2. with other inflammatory diseases (such as rheumatoid arthritis and inflammatory bowel disease, etc.). 3. a history of pulmonary surgery, or a diagnosis of malignant tumor recently. 4. a history of blood transfusion in 4 weeks. 5. participating in a double-blind drug clinical trial. 6. unable to walk. 7. using oral or intravenous steroid therapy. 8. with acute exacerbation in 4 weeks. For AECOPD: Inclusion Criteria: Patients who were over 40 years old were eligible for inclusion if they had a diagnosis of COPD in their primary care clinical record and were presenting with an acute exacerbation of respiratory symptoms.

Design outcomes

Primary

Measure	Time frame
Differentially expressed genes of 13 participants as assessed by RNA sequencing	through study completion, an average of 1 year

Countries

China

Outcome results